Higher levels of oxidized low density lipoproteins in Alzheimer's disease patients: Roles for platelet activating factor acetyl hydrolase and paraoxonase-1

Journal of Alzheimer's Disease

Volumn 46, Issue 1, 2015, Pages 179-186

  Bacchetti, Tiziana ^a   Vignini, Arianna ^a   Giulietti, Alessia ^a   Nanetti, Laura ^a   Provinciali, Leandro ^a   Luzzi, Simona ^a   Mazzanti, Laura ^a   Ferretti, Gianna ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alzheimer's disease; high density lipoproteins; lipid peroxidation; low density lipoproteins; oxidative stress; paraoxonase 1 (PON1); platelet activating factor acetyl hydrolase (PAF AH)

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN E4; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; LOW DENSITY LIPOPROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; MALE; MINI MENTAL STATE EXAMINATION; OXIDATIVE STRESS; PRIORITY JOURNAL; BLOOD; GENETICS; MENTAL HEALTH; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; STATISTICS; VERY ELDERLY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC;

EID: 84929314957     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143096     Document Type: Article

References (60)

1. Singh NK, Chhillar N, Banerjee BD, Bala K, Mukherjee AK, Mustafa MD, Mitrabasu (2012) Gene-environment interaction in Alzheimer's disease. Am J Alzheimers Dis Other Demen 27, 496-503.
2. Selkoe DJ (1993) Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16, 403-409.
3. Sobow T, Flirski M, Liberski PP (2004) Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. Acta Neurobiol Exp 64, 53-70.
4. Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G (2013) Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis. Neurobiol Dis 59, 100-110.
5. Zhao Y, Zhao BL (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013, 316523.
6. Padurariu M, Ciobica A, Lefter R, Serban IL, Stefanescu C, Chirita R (2013) The oxidative stress hypothesis in Alzheimer's disease. Psychiatr Danub 25, 401-409.
7. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68, 2092-2097.
8. Pratico D, V, Trojanowski MYL, Rokach JQ, Fitzgerald J, GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidationin vivo.FASEB J 12, 1777-1783.
9. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, Perry G (1998) Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2, 4-dinitrophenylhydrazine. J Histochem Cytochem 46, 731-735.
10. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17, 2653-2657.
11. Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schroder J, Kinscherf R (2008) Novel systemic markers for patients with Alzheimer disease?-a pilot study. Curr Alzheimer Res 5, 358-366.
12. Sinem F, Dildar K, Gokhan E, Melda B, Orhan Y, Filiz M (2010) The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res 7, 463-469.
13. Zhao Z, Zhou H, Peng Y, Qiu CH, Sun QY, Wang F, Xie HN (2014) Expression and significance of plasma 3-NT and ox-LDL in patients with Alzheimer's disease. Genet Mol Res 13, 8428-8435.
14. Kankaanpaa J, Turunen SP, Moilanen V, Horkko S, Remes AM (2009) Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease. Neurobiol Dis 33, 467-472.
15. Goswami B, Tayal D, Gupta N, Mallika V (2009) Paraox-onase:Amultifaceted biomolecule.Clin Chim Acta410, 1-12.
16. Kim DS, Marsillach J, Furlong CE, Jarvik GP (2013) Phar-macogenetics of paraoxonase activity: Elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 14, 1495-1515.
17. Tselepis AD, John Chapman M (2002) Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3, 57-68.
18. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogel-man AM (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res 41, 1495-1508.
19. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G (2001) Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38, 163-169.
20. Ferretti G, Bacchetti T, Marotti E, Curatola G (2003) Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity. Metabolism 52, 146-151.
21. De Keyzer D, Karabina SA, Wei W, Geeraert B, Stengel D, Marsillach J, Camps J, Holvoet P, Ninio E (2009) Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 29, 2041-2046.
22. Davidson JE, Lockhart A, Amos L, Stirnadel-Farrant HA, Mooser V, Sollberger M, Regeniter A, Monsch AU, Irizarry MC (2012) Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: A cross-sectional study. Alzheimers Res Ther 4, 51.
23. van Oijen M, van der Meer IM, Hofman A, Witteman JC, Koudstaal PJ, Breteler MM (2006) Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol 59, 139-144.
24. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM (1999) Lipoprotein-associated phospholi-pase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem J 338(Pt 2), 479-487.
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Schel-tens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's dis ease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
26. Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M (2008) Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities.J Agric Food Chem56, 8704-8713.
27. Menini T, Gugliucci A (2014) Paraoxonase 1 in neurological disorders. Redox Rep 19, 49-58.
28. Erlich PM, Lunetta KL, Cupples LA, Abraham CR, Green RC, Baldwin CT, Farrer LA (2012) Serum paraoxonase activity is associated with variantsin the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging 33, 1015 e1017-1023.
29. Cagnin A, Leon A, Vianello D, Colavito D, Favaretto S, Zarantonello G, Stecca A, Ermani M, Zambon A (2013) LDL density and oxidation are modulatedbyPON1 promoter genotype in patients with Alzheimer's disease. J Alzheimers Dis 34, 377-385.
30. Vikarunnessa S, Weiner MF, Vega GL (2013) LDL phenotype in subjects with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 36, 571-575.
31. Dildar K, Sinem F, Gokhan E, Orhan Y, Filiz M (2010) Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia. Alzheimer Dis Assoc Disord 24, 194-197.
32. Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: Arelationship with paraoxonase activity.Mult Scler 11, 677-682.
33. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V (2005) Paraoxonase activity in high-density lipoproteins: A comparison between healthy and obese females. J Clin Endocrinol Metab 90, 1728-1733.
34. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101, 1581-1590.
35. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D (2008) Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 49, 245-250.
36. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, Aviram M (2006) The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281, 7657-7665.
37. Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275, 3957-3962.
38. Borowczyk K, Shih DM, Jakubowski H (2012) Metabolism and neurotoxicity of homocysteine thiolactone in mice: Evidence for a protective role of paraoxonase 1. J Alzheimers Dis 30, 225-231.
39. Khodadadi S, Riazi GH, Ahmadian S, Hoveizi E, Karima O, Aryapour H (2012) Effect of N-homocysteinylation on physicochemical and cytotoxic properties of amyloid beta-peptide. FEBS Lett 586, 127-131.
40. Hershkowitz M, Adunsky A (1996) Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct dementia patients. Neurobiol Aging 17, 865-868.
41. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K (2003) Human paraoxonase-1 gene expression by HepG2 cells is downreg-ulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci 73, 2807-2815.
42. McCall MR, La Belle M, Forte TM, Krauss RM, Takanami Y, Tribble DL (1999) Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: Implications for LDL oxidative susceptibility. Biochim Biophys Acta 1437, 23-36.
43. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F (2001) Circulating oxidized LDL is auseful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21, 844-848.
44. Levitan I, Volkov S, Subbaiah PV (2010) Oxidized LDL: Diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 13, 39-75.
45. Ferretti G, Bacchetti T (2011) Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci 311, 92-97.
46. Wang H, Eckel RH (2014) What are lipoproteins doing in the brain? Trends Endocrinol Metab 25, 8-14.
47. Jeynes B, Provias J (2011) The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J Neurosci Res 89, 22-28.
48. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R (1997) A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J Cell Biol 138, 877-889.
49. Schreurs MP, Hubel CA, Bernstein IM, Jeyabalan A, Cipolla MJ (2013) Increased oxidized low-density lipoprotein causes blood-brain barrier disruption in early-onset preeclampsia through LOX-1. FASEB J 27, 1254-1263.
50. Mao X, Xie L, Greenberg DA (2014) LOX-1 expression and oxidized LDL uptake and toxicity in the HN33 neuronal cell line. Neurosci Lett 580, 182-185.
51. Neely MD, Montine TJ (2002) CSF lipoproteins and Alzheimer's disease. J Nutr Health Aging 6, 383-391.
52. Keller JN, Hanni KB, Gabbita SP, Friebe V, Mattson MP, Kindy MS (1999) Oxidized lipoproteins increase reactive oxygen species formation inmicroglia and astrocyte cell lines. Brain Res 830, 10-15.
53. Draczynska-Lusiak B, Doung A, Sun AY (1998) Oxidized lipoproteins may play a role in neuronal cell death in Alzheimer disease. Mol Chem Neuropathol 33, 139-148.
54. Schulz B, Liebisch G, Grandl M, Werner T, Barlage S, Schmitz G (2007) Beta-amyloid (Abeta40, Abeta42) binding to modified LDL accelerates macrophage foam cell formation. Biochim Biophys Acta 1771, 1335-1344.
55. Liapikos TA, Antonopoulou S, Karabina SP, Tsoukatos DC, Demopoulos CA, Tselepis AD (1994) Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta 1212, 353-360.
56. Giavarotti L, Simon KA, Azzalis LA, Fonseca FL, Lima AF, Freitas MC, Brunialti MK, Salomao R, Moscardi AA, Montano MB, Ramos LR, Junqueira VB (2013) Mild systemic oxidative stress in the subclinical stage of Alzheimer's disease. Oxid Med Cell Longev 2013, 609019.
57. Firoz CK, Jabir NR, Khan MS, Mahmoud M, Shakil S, Damanhouri GA, Zaidi SK, Tabrez S, Kamal MA (2015) An overview on the correlation of neurological disorders with cardiovascular disease. Saudi J Biol Sci 22, 19-23.
58. Stampfer MJ (2006) Cardiovascular disease and Alzheimer's disease: Common links. J Intern Med 260, 211-223.
59. Bhat NR (2010) Linking cardiometabolic disorders to sporadic Alzheimer's disease: A perspective on potential mechanisms and mediators. J Neurochem 115, 551-562.
60. Yang Y, Song W (2013) Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience 250, 140-150.